Pasar al contenido principal

PLASTICIDAD DE MICROGLÍA EN DEMENCIA

PID2021-129053OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

  • Rodríguez-Baena, Francisco Javier
  • Marquez-Galera, Angel
  • Ballesteros-Martínez, Pablo
  • Castillo, Alba
  • Díaz, Eva
  • Moreno-Bueno, Gema
  • López-Atalaya, José P.
  • Sánchez-Laorden, Berta
Melanoma is one of the tumor types with the highest risk of brain metastasis. However, the biology of melanoma brain metastasis and the role of the brain immune microenvironment in treatment responses are not yet fully understood. Using preclinical models and single-cell transcriptomics, we have identified a mechanism that enhances antitumor immunity in melanoma brain metastasis. We show that activation of the Rela/Nuclear Factor κB (NF-κB) pathway in microglia promotes melanoma brain metastasis. Targeting this pathway elicits microglia reprogramming toward a proinflammatory phenotype, which enhances antitumor immunity and reduces brain metastatic burden. Furthermore, we found that proinflammatory microglial markers in melanoma brain metastasis are associated with improved responses to immune checkpoint inhibitors in patients and targeting Rela/NF-κB pathway in mice improves responses to these therapies in the brain, suggesting a strategy to enhance antitumor immunity and responses to immune checkpoint inhibitors in patients with melanoma brain metastasis., We thank Angela Nieto for helpful discussions and suggestions along the project and the preparation of the manuscript and AG.de-la-Fuente for advice and assistance, particularly with flow cytometry experiments. We thank the Core Facilities and animal house for the technical support (Verona Villar, Giovanna Exposito, Antonio Caler, Josep Mulet, and Alvaro Fenoll). We thank Prof. Angel Barco for the Relatm1Asba mice, Prof. Larue for the 1014 cells, and the MD Anderson Foundation Biobank. This work was supported by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, co-financed by ERDF (MICINN-AEI, PID2022-141613OB-I00 [B.S-L.]; PID2021-129053OB-100 [J.P.L-A.]; PID2022-136854OB-I00 [G.M-B.]) and ISCIII (CIBERONC, CB16/12/00295 [G.M-B.]); the FERO Foundation [B.S-L.]; and Melanoma Research Alliance (https://doi.org/10.48050/pc.gr.91574 [B.S-L.]). F.J.R-B. held an GVA-APOSTD21 contract. We also acknowledge support from ICAR and the GEM group [B.S-L.] and the GVA (CIPROM/2021/045 [B.S.-L.] and PROMETEO/2020/007 [J.P.L-A.]), CSIC PTI-NEURO-AGING +, and Centro de Excelencia Severo Ochoa, grant CEX2021-001165-S, funded by MCIN/AEI/10.13039/501100011033. Illustrations were created with BioRender., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Whole transcriptome analysis of peripheral blood mononuclear cells from de novo and drug-naive Parkinson's disease patients

  • Navarrete, Francisco
  • Guillot-Fernández, Marina
  • Martínez-Hostyn, Lorena
  • Navarro, Daniela
  • Molina, José A.
  • López-Atalaya, José P.
  • Manzanares, Jorge
Blood-based biomarkers represent a highly convenient and minimally invasive method to improve the diagnosis of Parkinson's disease (PD), particularly at early stages. In this study, we present a comprehensive analysis of transcriptional changes in peripheral blood mononuclear cells (PBMCs) from de novo and drug-naive, recently diagnosed PD patients (n ​= ​23) and healthy sex- and age-matched controls (n ​= ​16). Whole-transcriptome analysis revealed differentially expressed genes (DEGs) in PBMCs from PD patients, including genes with immune-related functions such as CHI3L1, FAM198B, ID3, MDX1, and PROK2. Gene set enrichment analysis (GSEA) further identified alterations in immune pathways, including the IL-6/JAK/STAT3 signaling pathway and the complement cascade, associated with PD. We performed cross-validation using two independent whole-blood transcriptomic datasets from PD patients to assess the reproducibility and biological relevance of our findings. Both comparisons showed moderate but highly significant correlations in gene expression patterns. Overall, our results reveal robust and reproducible transcriptional alterations in PBMCs from early-stage PD patients, underscoring the contribution of immune dysregulation to PD pathogenesis. These findings support the potential of PBMC transcriptomics as a valuable platform for biomarker discovery in Parkinson's disease., We thank all the participants who donated samples for this study. We are also grateful to Jesica Portero Trigo for her excellent technical assistance in processing, optimizing and analyzing RNA samples from PD and CT subjects at the Multigenic Analysis Section of the Central Research Unit, Faculty of Medicine, Valencia. The International Center for Aging Research (ICAR) foundation funded the study for J.M., and one-year Fellowship to L.M.H. This work was supported by Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL) to J.M. M.G.F. holds an FPU-PhD Fellowship from the Spanish Ministry of Education (FPU22/01375). L.M.H. held a predoctoral Fellowship from the Fundación Tatiana Pérez de Guzmán el Bueno. J.P.L-A.'s research is supported by grants PID2021-129053OB-100 from AEI, co-financed by ERDF, and CIPROM/2023/15 from the GVA through the Prometeo Programme. The Instituto de Neurociencias is a Centre of Excellence Severo Ochoa (CEX2021-001165-S) funded by MCIN/AEI/10.13039/501100011033., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiscale Approximations to Understand the Complex Role of Microglia in Alzheimer's Disease

  • Martínez-Tazo, Patricia
  • Mejías-Ortega, Marina
  • López-López, Verónica
  • Bhojwani-Cabrera, Aysha M.
  • Saxton, Emma
  • Canals, Santiago
  • Hardingham, Giles E.
  • Gutiérrez, Antonia
  • López-Atalaya, José P.
  • De Santis, Silvia
Microglia, the resident innate immune cells of the central nervous system, play a pivotal role in the pathogenesis of Alzheimer's disease (AD). Microglia are now recognized as a highly dynamic and heterogeneous population whose molecular and functional states vary with spatial context, disease stage, and genetic background. Recent discoveries across multiple scales from genetics, molecular and cellular biology, to systems-level imaging and epidemiology have underscored the complex and context-dependent contributions of microglia to the AD cascade. Together, these findings highlight the need for integrative, multiscale approaches that bridge molecular, cellular, and systemic perspectives to elucidate the diverse roles of microglia and their impact on disease progression. This mini-review discusses recent advances in understanding microglial biology across these dimensions and outlines current challenges toward achieving a more unified and therapeutically oriented framework for studying microglia in AD., This work was supported by the Instituto de Salud Carlos III (PI24/00274), the Generalitat Valenciana (PROMETEO 2020/007, CIESGT/2025/06, CIPROM/2022/15, CIDEGENT/2021/015), the Ministerio de Ciencia e Innovación (PID2021-129053OB-I00, PID2021-128909NA-I00, CNS2023-144883, RTI2018-102260-B-I00, PID2021-128158NB-C21, PID2024-162400OB-C21, PCI2024-153491), the Fundacion Pasqual Maragall (2023–1296), the UK Dementia Research Institute, the Program for Centres of Excellence in R&D Severo Ochoa (CEX2021-001165-S) the Junta de Andalucía (CTS950-G-FEDER), and PMT is supported by the Spanish Ministry through a PhD fellowship FPU20/05737., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sex-dependent interferon signaling contributes to female-biased vulnerability in Alzheimer’s disease

  • López-López, Verónica
  • Iniesta, Gerard
  • Galán-Ganga, Marcos
  • Expósito-Coca, Alejandro
  • Durán-Laforet, Violeta
  • Bhojwani-Cabrera, Aysha M.
  • Navarrón, Carmen M.
  • Guillot-Fernández, Marina
  • Venero, José L.
  • Sánchez-Mut, José V.
  • Barco, Ángel
  • Giralt, Albert
  • López-Atalaya, José P.
[Data availability] The transcriptomics data sets generated in this study can be accessed at the GEO public repository using the accession number GSE304521 and GSE304362. In addition, publicly available single-cell RNA-seq data (GSE173242) were also reanalyzed as part of this study [46]. Human RNA-seq data used in this study were obtained from the publicly available The Mount Sinai Brain Bank (MSBB) study, hosted on the AD Knowledge Portal (https://adknowledgeportal.org/). The dataset is accessible via Synapse (https://www.synapse.org/): syn3159438; metadata: syn29855570; count data: syn27068754). The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org/). These data were generated from postmortem brain tissue collected through the Mount Sinai VA Medical Center Brain Bank and were provided by Dr. Eric Schadt from Mount Sinai School of Medicine. Processed data and code used for statistical analysis, gene expression processing, and Fig. generation are available upon request from the corresponding author., Alzheimer’s disease (AD) disproportionately affects women, yet the biological basis of this sex bias remains unclear. Here, we identify sex-dependent interferon signaling as a contributor to this disparity. Transcriptomic profiling of postmortem AD tissue and APP/PS1 mice revealed preferential enrichment of interferon-responsive gene programs in females. In APP/PS1 mice, heightened interferon responses were associated with increased neurodegenerative features, and single-cell transcriptomic analyses identified microglia as a major cellular compartment engaging interferon responses. To test causality, we manipulated interferon signaling in vivo. Acute systemic interferon activation promoted AD-like neuropathological alterations. Genetic amplification of interferon signaling in microglia exacerbated neuroinflammatory and neurodegenerative features in APP/PS1 mice, whereas pharmacological inhibition through cGAS-STING blockade suppressed interferon responses, reduced neuropathology, and preserved cognitive performance in female APP/PS1 mice. Together, these findings identify microglial interferon signaling as a modifiable contributor to AD-associated neuropathology and suggest a neuroimmune mechanism underlying the increased vulnerability of females to the disease., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. V.L-L. is the recipient of a 2021 neuroscience doctoral fellowship from the Fundación Tatiana Pérez de Guzmán el Bueno. G.I. holds a Formación de Personal Investigador (FPI) contract (CEX2021-001165-S-20–2), associated with “Severo Ochoa” grant CEX2021-001165-S from the MCIU/AEI/https://doi.org/10.13039/501100011033. M.G.-G received the support from “la Caixa” Foundation (ID 100010434), fellowship code is LCF/BQ/DR21/11880016. V.D-L holds a CIAPOS contract (CIAPOS/2024/131) funded by Generalitat Valenciana (GVA) and the European Social Fund Plus (ESF +). A.B-C. held a Formación de Personal Investigador (FPI) contract (PRE2019-090492), associated with grant RTI2018-102260-B-I00 awarded to J.P.L-A., and funded by MCIU/AEI/https://doi.org/10.13039/501100011033 and by “ERDF A way of making Europe”. M.G-F. is the recipient of a Formación de Profesorado Universitario contract (FPU22/01375) funded by the Spanish Ministry of Science, Innovation and Universities (MICIU). J.L.V research is supported by grant PID2024-157400OB-I00 funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and ERDF/EU. J.V.S.-M. research is supported by the Pasqual Maragall Foundation (PMRP/2022/1184), the MICIU/AEI/https://doi.org/10.13039/501100011033 and ERDF/EU (PID2022-143263OB-I00), and the Valencian Regional Government’s Prometeo Programme (PROMETEO/2021/045). A.B. research is supported by grants FCAIXA HR22-00394 from Fundación LaCaixa, PID2023-148442NB-I00 from AEI co-financed by ERDF, and CIPROM/2023/15 from the Generalitat Valenciana. A.G. research is supported by European Union NextGenerationEU/PRTR CNS2022—135391 (“Consolidación” program) and the Fundación Ramón Areces (CIVP21A7024). J.P.L-A. research is supported by MCIU/AEI/https://doi.org/10.13039/501100011033 and by ERDF, EU (PID2021-129053OB-I00; PID2024-163108OB-I00), and the Generalitat Valenciana, Conselleria d’Educació, Universitats i Ocupació (PROMETEO 2020/007; CIPROM/2023/15). The Institute of Neurosciences is a Severo Ochoa Center of Excellence (grant CEX2021-001165-S, funded by MCIU/AEI/https://doi.org/10.13039/501100011033)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001165-S)., Peer reviewed